Active, not recruitingNot applicableNCT03418844
Living After a Rare Cancer of the Ovary: Chronic Fatigue, Quality of Life and Late Effects of Chemotherapy
Studying Gonadal germ cell tumor
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Centre Francois Baclesse
- Principal Investigator
- Florence JOLYCentre François Baclesse
- Intervention
- Self-questionnaires of living conditions and quality of life(other)
- Enrollment
- 268 enrolled
- Eligibility
- 18 years · FEMALE
- Timeline
- 2018 – 2025
Study locations (19)
- HEGP, Paris, Paris, France
- Centre Paul Papin, Angers, France
- CHU Besançon Jean MINJOZ, Besançon, France
- Institut Bergonié, Bordeaux, France
- CH Fleyriat, Bourg-en-Bresse, France
- Centre François Baclesse, Caen, France
- Centre Jean Perrin, Clermont-Ferrand, France
- Centre Léon Berard, Lyon, France
- Institut Paoli Calmettes, Marseille, France
- Centre Catherine de Sienne, Nantes, France
- Institut de Cancérologie de l'Ouest, Nantes, France
- GH Cochin Broca Hôtel-Dieu, Paris, France
- Hôpital Diaconesses-Croix St Simon, Paris, France
- Institut Curie,, Paris, France
- Institut Gustave Roussy, Paris, France
- +4 more locations on ClinicalTrials.gov
Collaborators
ARCAGY/ GINECO GROUP
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT03418844 on ClinicalTrials.govOther trials for Gonadal germ cell tumor
Additional recruiting or active studies for the same condition.
- RECRUITINGNCT07318051Sample Collection for Ongoing Research and Product Evaluation StudyNatera, Inc.
- RECRUITINGNCT05645510LIVInG With chrONic Cancer TrEatments (LONGEVITI) StudyUniversity of Alberta
- RECRUITINGNANCT05142982Radiotherapy vs Observation for Post Chemotherapy Residual Mass in Advanced SeminomaTata Memorial Centre
- RECRUITINGNANCT05053230A Study Evaluating the Integrative Medicine at Home (IM@HOME) Program in People With CancerMemorial Sloan Kettering Cancer Center
- RECRUITINGPHASE1, PHASE2NCT04752826BI-1808 as a Single Agent and With Pembrolizumab (KEYTRUDA® ) in Treatment of Advanced Malignancies(Keynote-D20)BioInvent International AB
- ACTIVE NOT RECRUITINGPHASE1, PHASE2NCT04205227ENB003 Plus Pembrolizumab Phase 1b/2a in Solid TumorsENB Therapeutics, Inc
- ACTIVE NOT RECRUITINGPHASE1NCT03872947A Study of TRK-950 in Combinations With Anti-Cancer Treatment Regimens in Patients With Advanced Solid TumorsToray Industries, Inc
- RECRUITINGNANCT03787056Predictive Value of Progastrin Titer at Diagnosis and of Progastrin Kinetics During Treatment in Cancer PatientsHospices Civils de Lyon